Stock listing
BOATS:CBIO Crescent Biopharma, Inc. Stock
US listing (BOATS) of Crescent Biopharma, Inc. · home listing NASDAQ:CBIO
Follow Crescent Biopharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CBIO
$12.91 USD -0.57 (-4.2%)
Close on Nov 2, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CBIO
- Day range
- $12.68 – $13.92 USDNov 2, 2026
- Volume
- 147,307 sharesNov 2, 2026
- Market cap
- $479.5M USDAt the close on Nov 2, 2026 · price × 37.14M shares outstanding
- 52-week range
- $8.72 – $27.41 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $5.50M USDMedian day 250,400 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CBIO · Home | $12.91 USD | -0.57 (-4.2%) | 147,307 | $13.75 | $13.92 | $12.68 | $13.48 | Close on Nov 2, 2026 |
| Frankfurt:C68 | €11.90 EUR | +1.20 (+11.2%) | — | €11.90 | €11.90 | €11.90 | €10.70 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:CBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.91 | -0.57 | -4.2% | $13.75 | $13.92 | $12.68 | 147,307 | |
| $13.48 | -0.59 | -4.2% | $13.94 | $14.57 | $13.31 | 189,518 | |
| $14.07 | +0.57 | +4.2% | $13.66 | $14.94 | $13.56 | 378,000 | |
| $13.50 | +0.23 | +1.7% | $13.27 | $13.64 | $12.75 | 238,700 | |
| $13.27 | +0.51 | +4.0% | $12.81 | $13.47 | $12.56 | 288,200 | |
| $12.76 | -0.06 | -0.5% | $12.87 | $13.27 | $12.50 | 210,600 | |
| $12.82 | -0.32 | -2.4% | $13.36 | $13.36 | $12.62 | 397,800 | |
| $13.14 | -0.03 | -0.2% | $13.05 | $13.67 | $12.89 | 164,100 | |
| $13.17 | +0.10 | +0.8% | $13.16 | $13.81 | $13.12 | 250,400 | |
| $13.07 | +0.71 | +5.7% | $12.40 | $13.63 | $12.40 | 299,600 | |
| $12.36 | +0.52 | +4.4% | $11.91 | $12.94 | $11.82 | 230,700 | |
| $11.84 | -0.64 | -5.1% | $12.73 | $12.73 | $11.78 | 208,200 | |
| $12.48 | -0.10 | -0.8% | $12.62 | $13.19 | $12.31 | 295,900 | |
| $12.58 | -0.33 | -2.6% | $12.67 | $13.21 | $12.18 | 284,800 | |
| $12.91 | -1.55 | -10.7% | $14.46 | $14.67 | $12.85 | 197,100 | |
| $14.46 | -0.45 | -3.0% | $14.79 | $15.09 | $14.32 | 153,900 | |
| $14.91 | +0.79 | +5.6% | $14.07 | $15.28 | $14.07 | 347,100 | |
| $14.12 | +0.63 | +4.7% | $13.39 | $14.61 | $12.98 | 301,200 | |
| $13.49 | -0.08 | -0.6% | $13.47 | $14.20 | $13.27 | 1,049,300 | |
| $13.57 | -0.37 | -2.7% | $14.78 | $14.93 | $13.46 | 492,400 | |
| $13.94 | -0.38 | -2.7% | $14.42 | $14.42 | $13.63 | 187,000 | |
| $14.32 | +0.06 | +0.4% | $14.48 | $14.55 | $14.07 | 283,300 | |
| $14.26 | -0.33 | -2.3% | $14.61 | $14.73 | $14.10 | 300,900 | |
| $14.59 | -0.17 | -1.2% | $14.89 | $15.00 | $14.23 | 289,500 | |
| $14.76 | +0.23 | +1.6% | $14.66 | $15.62 | $14.16 | 684,600 | |
| $14.53 | +0.54 | +3.9% | $13.93 | $14.76 | $13.50 | 290,900 | |
| $13.99 | -0.25 | -1.8% | $14.29 | $14.46 | $13.66 | 228,700 | |
| $14.24 | +0.05 | +0.4% | $14.04 | $14.48 | $13.44 | 568,800 | |
| $14.19 | -2.25 | -13.7% | $16.37 | $16.47 | $13.70 | 727,700 | |
| $16.44 | +0.19 | +1.2% | $16.48 | $16.65 | $16.01 | 257,600 | |
| $16.25 | -0.64 | -3.8% | $16.93 | $17.04 | $15.76 | 375,800 | |
| $16.89 | +0.12 | +0.7% | $16.67 | $17.87 | $16.15 | 3,123,500 | |
| $16.77 | -0.41 | -2.4% | $17.60 | $18.57 | $16.32 | 665,900 | |
| $17.18 | -1.62 | -8.6% | $18.87 | $19.26 | $17.09 | 528,900 | |
| $18.80 | -0.88 | -4.5% | $19.60 | $20.31 | $18.40 | 358,000 | |
| $19.68 | +0.27 | +1.4% | $19.50 | $20.40 | $19.40 | 251,200 | |
| $19.41 | -0.05 | -0.3% | $19.81 | $20.35 | $19.11 | 264,400 | |
| $19.46 | -0.53 | -2.7% | $19.65 | $19.90 | $19.16 | 233,100 | |
| $19.99 | -0.47 | -2.3% | $20.30 | $20.91 | $19.92 | 296,000 | |
| $20.46 | -0.42 | -2.0% | $20.58 | $21.19 | $19.91 | 646,700 | |
| $20.88 | +0.48 | +2.4% | $20.09 | $21.53 | $20.09 | 239,700 | |
| $20.40 | +1.86 | +10.0% | $18.73 | $22.33 | $18.73 | 773,300 | |
| $18.54 | +0.61 | +3.4% | $18.00 | $19.01 | $17.93 | 214,900 | |
| $17.93 | +1.33 | +8.0% | $16.43 | $18.13 | $16.29 | 788,100 | |
| $16.60 | -1.15 | -6.5% | $17.65 | $17.65 | $16.14 | 163,000 | |
| $17.75 | -0.01 | -0.1% | $17.78 | $18.00 | $17.02 | 149,100 | |
| $17.76 | -0.26 | -1.4% | $17.89 | $18.26 | $17.50 | 76,700 | |
| $18.02 | +1.02 | +6.0% | $16.94 | $18.47 | $16.94 | 317,600 | |
| $17.00 | +0.03 | +0.2% | $17.12 | $17.66 | $16.87 | 129,700 | |
| $16.97 | -0.18 | -1.0% | $17.21 | $17.51 | $16.79 | 131,500 | |
| $17.15 | +0.92 | +5.7% | $16.39 | $17.19 | $16.03 | 218,400 | |
| $16.23 | -1.09 | -6.3% | $17.13 | $17.13 | $16.06 | 124,800 | |
| $17.32 | +0.63 | +3.8% | $17.14 | $17.50 | $16.59 | 170,200 | |
| $16.69 | -0.79 | -4.5% | $17.34 | $17.76 | $16.36 | 169,600 | |
| $17.48 | +0.34 | +2.0% | $17.14 | $18.06 | $16.96 | 126,100 | |
| $17.14 | +0.51 | +3.1% | $16.61 | $17.36 | $16.05 | 229,900 | |
| $16.63 | +0.20 | +1.2% | $16.53 | $16.85 | $16.14 | 120,400 | |
| $16.43 | -0.26 | -1.6% | $16.68 | $16.98 | $16.10 | 214,700 | |
| $16.69 | -0.64 | -3.7% | $17.38 | $17.42 | $16.59 | 96,600 | |
| $17.33 | +0.49 | +2.9% | $16.84 | $17.69 | $16.72 | 256,300 | |
| $16.84 | +0.41 | +2.5% | $16.72 | $17.13 | $16.47 | 150,700 | |
| $16.43 | +0.66 | +4.2% | $15.82 | $16.51 | $15.73 | 151,300 | |
| $15.77 | -0.61 | -3.7% | $16.44 | $16.94 | $15.57 | 184,300 | |
| $16.38 | +1.51 | +10.2% | $15.13 | $16.50 | $14.88 | 258,800 | |
| $14.87 | +0.40 | +2.8% | $14.82 | $15.09 | $14.00 | 236,400 |
- Ticker
- BOATS:CBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 15, 2026
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 56 slides
Calls
Replays
GlycoMimetics, Inc. (GLYC) Q1 2024 Earnings Call
Thu, May 09, 2024 · 8:30 AM ET
Watch TranscriptGlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call
Wed, Mar 27, 2024 · 8:30 AM ET
Watch TranscriptGlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call
Fri, Nov 03, 2023 · 8:30 AM ET
Watch Transcript
Latest news
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Oct 15, 2026
Closed $11.84 (-5.1%) on Oct 16, 2026
Crescent Biopharma Announces Grants of Inducement Awards
Oct 6, 2026
Closed $13.49 (-0.6%) on Oct 7, 2026
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Oct 5, 2026
Closed $13.94 (-2.7%) on Oct 5, 2026
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Jul 30, 2026
Closed $15.02 (+1.7%) on Jul 30, 2026
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jul 16, 2026
Closed $14.75 (-2.4%) on Jul 17, 2026
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Jul 14, 2026
Closed $15.67 (+2.4%) on Jul 15, 2026
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Jul 14, 2026
Closed $15.67 (+2.4%) on Jul 15, 2026
Crescent Biopharma to Present at June Investor Conferences
Jun 2, 2026
Closed $17.98 (+5.7%) on Jun 3, 2026
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
May 21, 2026
Closed $20.74 (+2.5%) on May 22, 2026
Crescent Biopharma to Present at May Investor Conferences
May 6, 2026
Closed $18.06 (-0.1%) on May 6, 2026
Financings
Public offering of ordinary shares and pre-funded warrants
Jul 30, 2026
Closed: US$143.7M in the latest tranche · US$14.5 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital
Announced Jul 14, 2026 · Update Jul 15, 2026 · Closed Jul 16, 2026 · Closed Jul 30, 2026
Decks
Investor Presentation (October 2026)
Investor deck · 56 slides · October 2026
Investor Presentation (December 2025)
Investor deck · 53 slides · Dec 4, 2025
Glycomimetics — Merger or Acquisition (April 2025)
Merger or acquisition · 27 slides · Apr 3, 2025
Glycomimetics — Merger or Acquisition (February 2025)
Merger or acquisition · 27 slides · Feb 28, 2025
Crescent Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 25 in all · newest Oct 15, 2026 · oldest 2025
- Calls
- 13 calls with a replay · 13 with a transcript · latest May 9, 2024
- Decks
- 6 decks · latest October 2026
Where Crescent Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CBIO · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A41BDZ | Lang & Schwarz | Germany | EUR |
| BOATS:CBIO · This page | BOATS | United States | USD |
| Frankfurt:C68 | Frankfurt | Germany | EUR |
| gettex:C68 | gettex | Germany | EUR |
Log in to ask 6ix AI your own questions about Crescent Biopharma, Inc.